Ravidasvir
- Generic Name
- Ravidasvir
- Drug Type
- Small Molecule
- Chemical Formula
- C42H50N8O6
- CAS Number
- 1242087-93-9
- Unique Ingredient Identifier
- AL3G001BI8
- Background
Ravidasvir is under investigation in clinical trial NCT02961426 (Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection).
- Indication
联合利托那韦强化的达诺瑞韦钠片和利巴韦林，用于治疗初治的基因1b型慢性丙型肝炎病毒感染的非肝硬化成人患者，不得作为单药治疗。
8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Muhammad Radzi Abu Hassan
- Target Recruit Count
- 322
- Registration Number
- NCT04885855
- Locations
- 🇲🇾
Hospital Sultanah Bahiyah, Alor Star, Kedah, Malaysia
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 249
- Registration Number
- NCT04745351
- Locations
- 🇺🇸
Holy Cross Hospital, Silver Spring, Maryland, United States
🇺🇸MedStar Health Research Institute, Washington, District of Columbia, United States
🇺🇸George Washington Medical Faculty Associates, Washington, District of Columbia, United States
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 584
- Registration Number
- NCT04501952
- Locations
- 🇺🇸
Mills Clinical Research, Los Angeles, California, United States
🇺🇸NorthStar Medical Center, Chicago, Illinois, United States
🇺🇸University of Maryland Baltimore, Baltimore, Maryland, United States
A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04358523
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
A Phase 1 Bioequivalence Study of a Test Tablet Formulation of Ravidasvir With the Reference Tablet Formulation of Ravidasvir Study
- Conditions
- Bioequivalence Study
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 37
- Registration Number
- NCT03602300
- Locations
- 🇲🇾
Ampang hospital, Ampang, Selangor, Malaysia
A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
- Conditions
- Chronic Hepatitis c
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03430830
- Locations
- 🇨🇳
First Hospital of Zhejiang Province, Hangzhou, Zhejiang, China
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
- Conditions
- HCV
- Interventions
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 425
- Registration Number
- NCT03362814
- Locations
- 🇨🇳
Peking University People's hospital, Beijing, Beijing, China
Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
- Conditions
- HCV
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03288636
- Locations
- 🇨🇳
The first hospital of Zhejiang province, Hangzhou, Zhejiang, China
Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03020095
Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03020134
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.